Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on WILMINGTON PLC. We currently have 29 research reports from 2 professional analysts.
|01Mar17 13:58||RNS||Voting Rights and Capital|
|24Feb17 14:29||RNS||Director/PDMR Shareholding|
|23Feb17 09:36||RNS||Interim Results - Update|
|23Feb17 07:00||RNS||Interim Results|
|01Feb17 13:10||RNS||Voting Rights and Capital|
|01Feb17 07:00||RNS||Completion of Health Service Journal|
|19Jan17 07:04||RNS||Acquisition of Health Service Journal|
Frequency of research reports
Research reports on
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
Actual Experience (ACT LN) 2017 – a milestone year for revenue | Bagir Group (BAGR LN) Independent NED appointment to strengthen Board composition | Bioquell (BQE LN) Reassuring pre-close statement | Carador Income Fund (CIFU LN) Q4 dividend increased to 2.75c, 0.5c higher than forecast | FreeAgent (FREE LN) Contract with Royal Bank of Scotland | Halfords Group (HFD LN) Excellent Q3 update, special divi and confidence in FX mitigations | N Brown Group (BWNG LN) Robust peak trading with reversal of drag from older titles | NCC Group (NCC LN) Interims confirm underlying business sound | St Ives (SIV LN) Downgrade | Summit Therapeutics (SUMM LN) Dr David Roblin appointed Chief Operating Officer and R&D President | Wilmington Group (WIL LN) Acquisition – Further scaling of Healthcare
N+1 Singer - Morning Song 03-11-2016
03 Nov 16
blur Group (BLUR LN) Q3 trading update | Earthport (EPO LN) Approval for outbound services for banks in India | Eckoh (ECK LN) Appointment of new CFO | H&T Group (HAT LN) FY16e to exceed expectations on impact of higher H2 gold price | Howden Joinery Group (HWDN LN) In line FY16 but strengthening headwinds result in FY17 downgrades | Low & Bonar (LWB LN) Solid Update | SDL (SDL LN) Disposal of campaigns business; more to come | Spirent Communications (SPT LN) Progress but revenue remains lumpy | Wilmington Group (WIL LN) Q1 In-line
N+1 Singer - Wilmington Group - Acquisition upgrades
25 Jul 16
Wilmington announced the acquisition of SWAT Group Limited last week. The business provides training and technical compliance support to accountancy businesses in London and the South West. This will bolster the range of accountancy services offered by the Finance division and extend its geographic range in the UK. SWATs revenues are derived in broadly equal proportions from training and information & consultancy. An attractive purchase price (we estimate c5x EBIT) helps make a modest acquisition material at the EPS line, enhancing our FY17 by 2.3% and FY18 by 2.5%. FY17 EPS growth is now 11.7%. There is further substantial capacity to acquire and boost this growth further (by double digit %) and increase the potential exploitation of the secular global growth trend in compliance and regulation. Our Target Price rises to 339p and based on a 12 month TSR of 40.9% we reiterate our Buy rating.
N+1 Singer - Strategy - Brexit – a few thoughts in mid and small cap
27 Jun 16
Friday’s “surprise” referendum vote still has of course a very long way to play out in terms of political, geo-political and economic ramifications, though the initial movements in markets and currencies were not a surprise given the obvious shock and uncertainty. In this piece we offer a few thoughts on our coverage universe going forward, both where our views are evolving and where existing themes are reinforced. Sectors under more pressure than before include: Consumer, General Retail, Construction & Support Services. Sectors where our existing themes should prove more resilient include: Technology, Life Sciences and Healthcare and much of General Financials – though with some caveats. In most sectors interesting opportunities/angles are arising – currency and potential M&A being obvious examples in the Industrials, Tech, Heallthcare and Media sectors.
24 Feb 16
H1 shows good progress in the powerhouse units, Risk & Compliance and Finance delivering strong growth. The FRA acquisition is working well and International revenues have increased to 42% of group vs a 38% comp. The Insight unit has been impacted by competition in some lower end products. WIL decided some time ago to avoid these areas so we are lee concerned about this. Short term ambiguity in legal training competency requirements is impacting the Legal CPD training business that appeared to be on track to stabilise. The group plans to accelerate integration within the legal unit (3 businesses) to improve profitability. We expect to shave off c£0.2m from EBIT to reflect the Legal/Insight drags. The Group has made a confident statement about the outlook and we flag strong deferred revenue growth of 6% (to £21.3m) showing good growth in visible quality revenues. This bodes well for momentum in H2 and FY17. While there are some small irritations the WIL investment case is on track for strong high quality value creation. We maintain our Buy rating.
16 Mar 17
4imprint (FOUR): 6% dividend yield for a growth stock? (BUY) | Cambridge Cognition* (COG): Amgen uses CANTAB technology in trial (CORP) | Seeing Machines* (SEE): H1 results show steady operational progress (CORP) | Allergy Therapeutics (AGY): Pollinex Quattro Birch Ph III EU trial starts (BUY) | Capital Drilling* (CAPD): FY results in line, with turnaround in exploration activity (CORP)
M&A coming to a company near you?
16 Mar 17
Markets have retained their relative strength over the last fortnight. We have seen a mixed reaction to the Budget last week, the passing of the Brexit Bill earlier in the week and the first interest rate hike by the Federal Reserve in the US yesterday. Against this backdrop, we have seen some notable M&A activity across a range of sectors which may move down the market capitalisation scale. We now face an extended period of heightened speculation but “no running commentary” regarding Brexit in the UK after Article 50 is triggered at the end of the month.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
6% dividend yield for a growth stock?
16 Mar 17
4imprint’s proven operating model continues to steadily gain market share from a low base. Capital requirements are low, acquisitions unlikely, pension risk significantly reduced and, hence, future cash flow is likely to be returned to shareholders. We expect the current $22m net cash balance to be retained, providing a cushion against any macro downturns, and dividend growth to continue to match EPS, supplemented by special dividends when net cash builds (possibly every other year). As such, the free cash flow yield, 5.1% in FY2018E 5.8% in FY 2019E, is a proxy for the dividend yield, highly attractive in our view for a proven growth stock.
10 Mar 17
We have run our new quantitative Slide Rule over the Support Services sector. Of the c.500 stocks we have ranked on a Quality, Value, Growth and Momentum basis in the small to mid-cap space, 21 Support Services stocks appear in the top 100. Fulcrum leads the pack, ranked no. 6 out of 500 (and not coincidentally our top pick for the year), closely followed by Brainjuicer (no.7), Sanne (no.8), Learning Technologies (no. 12) and Next Fifteen (no.16). These stocks have high ROCE on both an EBIT and cash basis, strong growth prospects, earnings and share price momentum and valuations that, in this context, remain attractive. At the other end of the spectrum, HSS, Management Consulting, Serco, Mitie and Lakehouse appear towards the bottom of the rankings. Strong returns could, of course, be made if any of these turn their fortunes around, and management has been changed at Lakehouse, Serco and Mitie.